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I a. ABSTRACT 
 
Background: Recent epidemiological studies suggest that chemotherapy has not 
contributed to a marked improvement of patient outcome during the last decades. In 
most randomized trials which investigated the efficacy of a 1st-line schedule for 
metastatic breast cancer (MBC), the median survival ranged between 18 and 24 
months. The goal of the present study was to analyse the survival of patients with 
MBC treated in a single university outpatient clinic. 
Methods: Patients who had received their complete anti-cancer treatment for MBC in 
our outpatient clinic between 2000 and 2005 were analyzed for treatment and 
survival.  
Results: 232 patients [median age of 53, range 27-87 yrs; ER and/or PgR positive 
(HR+) n=174 (75%); HER2 over-expression (HER2+) n=79 (34%)] were included in 
the analysis. Endocrine sensitive patients received 1-2 (58.6%), 3-4 (37.4%) and 5-6 
(2.3%) hormonal regimens.  Of all patients 53.4% received up to 3 cytostatic agents 
in palliative intent, 4-6 regimens were applied in 22.1% and 12.9% received more 
than 6 subsequent regimens during the course of their disease.  
The median overall survival (OS) from time of diagnosis of metastatic disease was 44 
months. Patients with HR positive tumours survived 46 months, whereas the survival 
of those with HR negative tumours was 34 months (p=0.07). HER2+ patients who 
received trastuzumab survived for a median of 44 months. Visceral involvement was 
associated with a shorter survival as compared to non-visceral disease (34 vs. 57 
months, p<0.05). Thirty-one patients underwent loco-regional procedures as 
resection of metastases (n=14, 6.0%) or radiofrequency ablation (n=17, 7.3%). 
Conclusion: These data show a selective patient population in a single-centre 
setting, that report improved survival rates. Whether innovative medicine, a step by 
2 
 
step escalation of all treatment modalities according to standard guidelines and 
individualized clinical requirements and a multidisciplinary treatment approach 
contribute to these good outcomes is debatable. 
 
Key words: metastatic breast cancer, survival, chemotherapy, endocrine therapy, 
therapy sequences  
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I b. ZUSAMMENFASSUNG 
  
Hintergrund: Jüngst veröffentlichte epidemiologische Studien zeigen, dass die 
Chemotherapie in den letzten Jahrzehnten nicht zu einer Verbesserung der 
Überlebenszeit beim metastasierten Mammakarzinom (MBC) beigetragen hat. In den 
meisten randomisierten Studien, welche die Effektivität einer systemischen “first-line” 
Therapie beim MBC untersucht haben, wird die mediane Überlebenszeit mit 18 bis 
24 Monaten angegeben. Ziel dieser retrospektiven Studie war daher die Analyse der 
Überlebenszeit von MBC-Patientinnen, die in einer universitären Spezialambulanz 
behandelt wurden.  
Methoden: Alle Patientinnen mit MBC, die im Zeitraum von 2000 – 2005 in unserer 
Spezialambulanz behandelt wurden, konnten bezüglich Therapiesequenz und 
Überlebenszeit ausgewertet werden.  
Ergebnisse: 232 Patientinnen [medianes Alter  53 Jahre, Altersspanne 27-87 Jahre; 
ER und/oder PgR positiv (HR+) n=174 (75%); HER2 Überexpression (HER2+) n=79 
(34%)] wurden in die Analyse aufgenommen. Als anti-hormonelle Therapie erhielten 
HR+ Patientinnen 1-2 (58.6%), 3-4 (37.4%) und 5-6 (2.3%) Therapiesequenzen. 
Dreiundfünfzig Prozent aller Patientinnen erhielten bis zu 3 
Chemotherapiesequenzen in palliativer Intention, 4-6 Sequenzen wurden bei 22.1% 
verabreicht und 12.9% erhielten mehr als 6 verschiedene zytostatische Therapien im 
Verlauf der Erkrankung. Die mediane Überlebenszeit ab dem Zeitpunkt der 
Metastasierung betrug 44 Monate. Patientinnen mit HR positiven Tumoren 
überlebten ebenfalls 46 Monate, während Patientinnen mit HR negativen Tumoren 
Überlebenszeiten von 34 Monaten (p=0.07) zeigten. HER2+ Patientinnen, die 
Trastuzumab bekommen hatten, überlebten im Median 44 Monate. Die mediane 
Überlebenszeit bei viszeraler Metastasierung war im Vergleich zu nicht viszeraler 
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Erkrankung prognostisch ungünstiger (34 vs. 57 Monate, p<0.05). Einunddreißig 
Patientinnen wurden einer lokalen Therapie der Metastasen unterzogen 
[Metastasenresektion (n=14, 6,0%) oder Radiofrequenz-Ablation (n=17, 7.3%)].  
Schlussfolgerung: Unsere Daten, die an einer selektiven Patientenkohorte in einem 
einzigen Klinikzentrum erhoben wurden, zeigen verbesserte Überlebensraten. 
Möglicherweise ist dies durch innovative Medizin, eine schrittweise Eskalation aller 
Therapiemodalitäten entsprechend standardisierten Therapieempfehlungen, 
individualisierte klinische Anforderungen und einen multidisziplinären Therapieansatz 
mit bedingt. 
 
Schlüsselwörter: metastasiertes Mammakarzinom, Überlebensrate, 
Chemotherapie, hormonale Therapie, Therapiesequenzen.  
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1. BREAST CANCER  
1.1 BACKGROUND 
In Germany, as in most other developed countries, breast cancer is the most 
common cancer observed in women. In Northern and Western Europe the incidence 
of breast cancer is 70-110/100.000. Overall, breast cancer will strike one of every 10 
females in Western countries.  
 
Despite advances in the treatment of breast cancer, approximately 30% of women 
initially diagnosed with earlier stages of breast cancer eventually develop recurrent, 
advanced or metastatic disease. As an initial presentation, metastatic breast cancer 
(MBC) is uncommon, occurring in only about 6-10% of newly diagnosed cases1,2. 
The prognosis of patients who develop metastases varies based on the site of 
metastases. Patients with local/regional or bone sites have a more favourable 
prognosis than patients who have visceral or central nervous system metastases. 
Studies have also shown that survival is inversely proportional to the number of 
anatomical sites of metastasis at the time of relapse3.  
 
Once metastases have been detected, goals of therapy are to ameliorate symptoms, 
delay disease progression, improve or at least maintain quality of life and prolong 
overall survival. For most women diagnosed with metastatic breast cancer, median 
survival time durations of 18 to 24 months after diagnosis are common4,5. Some 
retrospective studies report long-term survivors up to 35 months6,7. 
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1.2.  PROGNOSIS  
1.2.1  RISK FACTORS  
The tumor registry in Munich estimated the average lifetime risk (as noted above) of 
breast cancer in the female population of Western countries at birth is 10 percent. 
Many studies have evaluated risk factors for breast cancer. Some risk factors have 
been consistently associated with an increased risk and were reviewed by Armstrong 
et al. and Veronesi et al. (Table 1)8,9.  
 
Table 1.   Established Risk Factors of Breast Cancer  
 
 
 
The association between breast cancer risk and breastfeeding or parity has been 
well established. Early age at first term birth is related to lifetime reduction in risk. 
Increased parity is associated with a long-term risk reduction. A nulli-parous woman 
has approximately the same risk as a woman with a first term birth at an age of about 
30 years. Relative risk falls by 4.3% for every 12 months of breastfeeding in addition 
to a 7% reduction for every birth. The absence of short-lifetime duration of 
breastfeeding that is typical for women in developed countries substantially 
contributes to the high incidence of breast cancer in these areas9. Other risk factors 
 
Risk Factor 
 
 
Relative Risk 
Age (≥50 vs. <50 years) 6.5 
Geographical location (developed countries) 
Family history of breast cancer 
     First-degree relative 
     Second-degree relative 
5 
1.4-13.6 
1.5-1.8 
Age at menarche (<12 vs. 14 years) 1.2-1.5 
Age at menopause (≥55 vs. <55 years) 1.5-2.0 
Age at first live birth (>30 vs. <20 years) 1.3-2.2 
Benign breast disease 
     Breast biopsy (any histologic finding) 
     Atypical hyperplasia 
 
1.5-1.8 
4.0-4.4 
Hormone-replacement therapy 1.0-1.5 
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have been less consistently associated with breast cancer (such as diet, use of oral-
contraceptives, lactation, and abortion) or are rare in the general population (such as 
radiation exposure), and are not included in currently used models to predict the risk 
of breast cancer8. 
Two major breast-cancer-susceptibility genes have been identified, BRCA1 and 
BRCA210,11. Women with mutations in either of these genes have a lifetime risk of 
breast cancer of 60 to 85 percent and a lifetime risk of ovarian cancer of 15 to 40 
percent. The presence of certain major risk factors in a given family, or combinations 
of risk factors, has been proposed as a reasonable criterion for consideration of 
testing for BRCA mutations (Table 2)8. 
 
Table 2.  Risk factors for carrying BRCA1 or BRCA2 mutation 
 
 
Family-History Risk Factors for carrying a BRCA1 or BRCA2 mutation 
 
 Known BRCA1 or BRCA2 mutation  
 Breast and ovarian cancer 
 Two or more family members under 50 years of age with breast cancer 
 Male breast cancer 
 One or more family members under 50 years of age with breast cancer plus 
Ashkenazi ancestry 
 Ovarian cancer plus Ashkenazi ancestry 
 
For women without risk factors for a BRCA mutation, genetic testing is unlikely to 
provide useful information about breast-cancer risk. Women who test negative are at 
the same risk as women without a family history of breast cancer8.  
 
1.2.2  PROGNOSTIC FACTORS  
Prognostic factors estimate prospectively the course of disease for an individual 
patient. Distinct from prognostic factors are predictive factors; these provide an 
indication of the response expected following therapy. 
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Standard predictive factors include hormone receptor status for selection of 
endocrine therapy and HER2 amplification and/or over-expression for selection of 
trastuzumab as a treatment modality in the metastatic setting12.  Hormone receptor 
status is not only important for determining the potential effects of endocrine therapy, 
but newly reported data suggest that primary chemotherapy in endocrine 
unresponsive tumours is more effective13-15.  
Standard prognostic factors include clinical and pathological staging, especially 
lymph node status and tumor size, and further tumor grade, histologic type, estrogen, 
progestarone- and HER2/neu receptor status.  
 
Recent attention has been focussed on a new classification system that uses the 
three common molecular markers, estrogen receptor (ER), progestarone receptor 
(PgR) and Her2/neu, and classifies patients into subtypes16-18. Luminal subtypes 
make up the hormone receptor positive tumours with a generally favourable 
prognosis. Most of the Her2 over-expressing tumours are hormone receptor negative 
and have specific gene expression patterns (HER2-subtype). The subtype of the 
basal-like tumours lacks both hormone receptor and HER2/neu expression, and has 
a poor prognosis.    
 
More potential prognostic factors have been reported in the last decade12. Two of 
these are detection of bone marrow metastases and recognition of simultaneous 
multiple gene expression patterns, or “signatures”.  
A Norwegian study reported that in addition to baseline bone marrow status, micro-
metastases formed three to four years after primary therapy are associated with a 
high rate of recurrence during the following years. The presence or absence of micro-
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metastases might not only improve the accuracy of staging but might also be helpful 
in stratifying breast cancer patients for different treatment modalities in the future19. 
 
With gene expression profiling, breast tumours can be classified into different 
subtypes, with significant difference in patient outcome20,21. Several groups have 
identified panels of gene expression markers with microarray-technology that appear 
to predict the likelihood of breast cancer recurrence in various populations of women 
with node negative disease9,20. A large proportion of these women would be disease-
free at 10 years without systemic treatment or with tamoxifen alone. Consequently, 
many women with early breast cancer are probably over-treated, resulting in 
decreased quality of life for these patients as well as an increased economic burden 
of this disease on society.  
 
1.3. SYSTEMIC TREATMENT OF METASTATIC BREAST CANCER 
Systemic treatment has produced significant responses in patients with metastatic 
disease in the last decades. Many changes have been made in the mainstay of 
regimens, and as science is constantly advancing, many changes are still to come 
with a common goal: to improve the efficacy and tolerability of the individual 
treatment for each patient and with that prolongation of overall survival. 
 
General treatment strategies for patients with MBC are summarized in the guidelines 
of the AGO (“Arbeitsgemeinschaft für Gynaecologische Onkologie”). These 
guidelines (2009) recommend for the treatment of MBC;  
1) anti-endocrine treatment for hormonal positive disease,  
2) chemotherapy in hormone negative disease or visceral organ involvement,  
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3) single agent therapy is preferred before combination therapy and  
4) the integration of targeted therapies with HER2 positive tumours.  
 
Mono-chemotherapy is specifically indicated for the treatment of MBC in the case of 
slow, not life threatening progression and when the tumor is insensitive to or shows 
progression during endocrine treatment. Poly-chemotherapy is indicated to achieve a 
rapid remission in the case of extensive symptoms of MBC and imminent life-
threatening metastases. The choice of the chemotherapeutic agent to be used 
depends on the aggressiveness of disease and localization of metastases, history of 
prior treatment and response rate, general health condition and age, and patients’ 
preferences15. Figure 4. gives a flow-diagram of the treatment of MBC. 
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Figure 4.  Therapy of MBC.  
 
Source:TZM Manual Mammakarzinome, V.Heinemann, W. Abenhardt, G. Bastert et al.  
 
1.3.1  ENDOCRINE THERAPY 
Hormones have been demonstrated to play a very important role in breast cancer 
oncogenesis and progression. The roots of endocrine therapy lie in blocking the 
estrogen production by removing estrogen production organs (ablative therapy, like 
oophorectomy for premenopausal women and adrenalectomy in postmenopausal 
women), or by interfering at a cellular level with estrogen and its receptor (additive 
therapy), or additional hormonal axes.  
 
Pre-menopausal
Post-menopausal
1. Elimination of ovarian function (GnRH-agonists/Operation/Radiotherapy) and Tamoxifen
2. GnRH-agonist and Aromatase inhibitor
3. GnRH-agonist and Progestagen
1. Antiestrogen or Aromatase inhibitor
2. Aromatase inhibitor or Antiestrogen
3. Progestagen
only Aromatase inhibitor after oophorectomy or radiotherapy
Mono-chemotherapyslow progression
minor discomfort
fast progression
strong discomfort
- with non-response
- with strong discomfort
- after last step of hormonal therapy
Cytostatic Therapy
Hormonal Therapy
Primary Cytostatic Therapy
- with fast progression of tumor
- with strong discomfort
- with negative receptor status of tumor/metastasis
strong discomfort
fast progression
Reduced general condition
Poly-chemotherapy
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Antiestrogenes or SERM´s, aromatase inhibitors, GnRH-agonists, estrogene receptor 
antagonists, and progestarones are endocrine treatment modalities for advanced or 
metastasized breast cancer and continuously in development. Table 6. gives an 
overview of endocrine treatment options. The SERM tamoxifen and the aromatase 
inhibitors are more specified below. 
 
Table 6.  Overview of endocrine therapies. 
Antiestrogens Tamoxifen (Novadex) 
Toremifen (Fareston) 
Aromatase Inhibitors Anastrozole (Arimidex) 
Letrozole (Femara) 
Exemestane (Aromasin) 
GnRH-Analogues Goserelin (Zoladex) 
Leuprorelin (Enantone-Gyn) 
Estrogen receptor antagonists Fulvestrant (Faslodex) 
Gestagens Medroxyprogesteronacetate 
(Clinovir) 
Megestrolacetate (Megestat) 
 
Patients with MBC and a favourable prognosis; relapse >2 years from first diagnosis, 
no visceral metastasis and positive hormone receptor status (estrogen and/or 
progestarone) should, primarily, be treated with endocrine therapy3, see Figure 4. 
Patients with a negative estrogen- and progestarone receptor status should not be 
treated with endocrine therapy, because a response rate of less than 10% is to be 
expected. The response rate to endocrine therapy is comparable with the response 
rate to mono-chemotherapy. On the other hand, the toxicity from cytostatic treatment 
is higher than that from endocrine treatment, with mono-chemotherapy having less 
toxicity than poly-chemotherapy. In contrast to endocrine therapy, a quicker response 
can be achieved with chemotherapy.  
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When the disease has metastasized, endocrine therapy should not be the first 
treatment of choice in the following situations:  
a)    fast disease progression,  
b)  symptomatic disease (outside bone-metastases, these can be treated with     
radiotherapy), and  
c)    a negative hormone receptor status15.  
 
1.3.1.1 TAMOXIFEN 
The anti-estrogene tamoxifen has been the most widely used endocrine therapy for 
breast cancer for more than 30 years. Tamoxifen was meant to be an anti-estogenic 
drug, but later was found to have estrogenic stimulation effects in bone, liver and 
endometrial tissue. It is now called selective estrogene receptor modulator (SERM).  
Tamoxifen is first-line endocrine therapy for premenopausal women with advanced 
breast cancer and positive hormone receptor status. It is a standard option for 
postmenopausal women as well, although more recent data suggest that aromatase 
inhibitors are a more effective choice than tamoxifen (see chapter 2 discussion on 
aromatase inhibitors). Tamoxifen is taken orally, at a dose of 20 mg daily. Between 
50 and 60 percent of women whose breast cancers are ER and/or PR-positive will 
respond to tamoxifen therapy. In contrast, fewer than 10 percent of women with 
metastatic hormone receptor-negative breast cancers respond to tamoxifen23. The 
majority of breast cancers that initially respond remain sensitive to tamoxifen for at 
least 12 to 18 months, and some continue to respond for several years. Some 
ER/PR-positive breast cancers are primarily resistant to tamoxifen; secondary 
resistance and resistance after initial response, also may occur. Resistance to 
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tamoxifen does not necessarily imply resistance to other endocrine therapies, see 
Figure 4.  
 
1.3.1.2 AROMATASE INHIBITORS 
In postmenopausal women, estrogen is no longer produced in the ovaries but 
androgens (mainly from the adrenal glands) are converted into estrogens in 
peripheral tissue by the enzyme aromatase. Aromatase inhibitors (AIs) act 
systematically to inhibit estrogen synthesis in tissues. AIs are classified as either first, 
second or third generation. Aminoglutethimide was the first aromatase inhibitor in 
clinical use (first generation) and had a similar tumor-regressing effect to other 
endocrine treatments, which showed the potential of this alternative type of therapy, 
however it was poorly tolerated. Other AIs have since been developed and the third 
generation AI´s (anastrozole, exemestane and letrozole) is in current use. Mouridsen 
et al. showed in a Phase III clinical trial that letrozole was superior to tamoxifen use 
in time to progression (median, 9.4 v 6.0 months, respectively; P <.0001) and overall 
objective response rate (32% v 21%, respectively; P =.0002). Median overall survival 
(OS) was slightly prolonged, but showed no significance, with 34 months for the 
letrozole arm versus 30 months for the tamoxifen22 treatment. Paridaens RJ et al. 
evaluated the efficacy of exemestane versus tamoxifen as first-line treatment for 
MBC in postmenopausal women until disease progression or unacceptable toxicity 
occurred. Exemestane showed a better overall response rate (46% v 31%; odds ratio 
= 1.85; 95% CI, 1.21 to 2.82; P=.005),  and median progression-free survival (PFS) 
was longer than with tamoxifen (9.9 v 5.8 months) but no longer-term benefit was 
shown in PFS and OS between both study arms23.  These studies, among others, led 
to the administration of anastrozole and letrozole as first-line treatment for MBC. 
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Exemestane is administered as second-line treatment. The question still remains 
whether OS is improved by treatment with AI´s.  
1.3.2 CHEMOTHERAPY 
In the primary therapy of MBC, mono-chemotherapy can achieve remission rates of 
25-68%, which can be improved by poly-chemotherapy schedules to 35-80%. There 
are a number of agents with established single-agent activity, with antracyclines and 
taxanes generally considered the most active1,24 
Table 7.  Most commonly used poly-chemotherapeutic schedules. 
 
 
Abbreviation 
 
Agents 
 
Dosage 
 
Repetition 
 
CMF Cyclophosphamide 
Methotrexate 
Fluorouracil 
600 mg/m2 i.v. 
40 mg/m2 i.v. 
600 mg/m2 i.v. 
Every third 
week 
EC Epirubicin 
Cyclophosphamide 
60 mg/m2 i.v. 
600 mg/m2 i.v. 
Every fourth 
week 
FEC Fluorouracil 
Epirubicin 
Cyclophosphamide 
500 mg/m2 i.v. 
75 mg/m2 i.v. 
500 mg/m2 i.v. 
Every third 
week 
FAC Fluorouracil 
Adriamycin 
Cyclophosphamide 
500 mg/m2 i.v. 
50 mg/m2 i.v. 
500 mg/m2 i.v. 
Every third 
week 
AC Adriamycin 
Cyclophosphamide 
60/50 mg/m2 i.v. 
600 mg/m2 i.v. 
Every third 
week 
GemPac Gemcitabine 
Paclitaxel 
1250 mg/m2i.v. Day 1/8 
175 mg/m2/3 hours i.v. 
Day 1 
Every third 
week 
ADoc Adriamycin 
Docetaxel 
50 mg/m2 i.v. 
75 mg/m2/1 hour i.v. 
Every third 
week 
EDoc Epirubicin 
Docetaxel 
60 mg/m2 i.v. 
75 mg/m2/1 hour i.v. 
Every third 
week 
CapDoc Capecitabine 
 
Docetaxel 
2x1250 mg/m2 i.v. Day 
1-1475 mg/m2 i.v. Day 1 
Every third 
week 
VinMito Vinorelbine 
Mitomycin C 
25 mg/m2 i.v. Day 1/8 
8 mg/m2 i.v. 
Every fourth 
week 
GemCis Gemcitabine 
Cisplatin 
750 mg/m2 i.v. Day 1/8 
30 mg/m2 i.v. Day 1/8 
Every third 
week 
19 
 
In addition, capecitabine (Xeloda), gemcitabine (Gemzar) and vinorelbine (Navelbine) 
have also demonstrated substantial activity in the metastatic setting25. Table 7. gives 
an overview of the different poly-chemotherapeutic schedules being given for MBC.  
 
As the effect of taxanes on survival compared with other drugs was still unclear, 
Ghersi et al. published a review article describing taxane-containing regimens for 
MBC. This review concluded that despite the relative immaturity of many of the 
included studies, there was sufficient evidence that, on average, taxane-containing 
regimens were associated with a statistically significant improvement in overall 
survival (HR of 0.93 95% CI 0.86-1.00, P=0.05) compared with non-taxane-
containing regimens. Further, the review concluded that docetaxel might be more 
effective than paclitaxel, given in three-weekly schedules24. This conclusion was 
supported by a phase III study where Jones et al. compared docetaxel with paclitaxel 
and found docetaxel superior to paclitaxel in time to progression, response duration 
and overall survival26. 
 
The use of poly-chemotherapy versus mono-chemotherapy or sequential single 
agents remains a subject of debate. Depending on the individual patient and specific 
treatment goals, either can be appropriate. Sequential single-agent therapy is 
frequently used for the management of asymptomatic patients with MBC. For 
patients with more extensive or symptomatic disease, oncologists prefer combination 
therapy 27. Combination therapies generally result in higher overall response rates 
and times to disease progression than with sequential single agents, but usually at a 
cost of greater toxicity. In addition, the higher overall response rates with combination 
therapy versus sequential single agents may not necessarily translate into superior 
survival outcomes1,27. O’Shaugnessy showed in a review article that combination 
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therapies like doxorubicin + paclitaxel, doxorubicin + docetaxel and epirubicin + 
paclitaxel showed benefits in median response rates and median overall time to 
treatment failure but no improvement in overall survival rates1. 
 
Passardi et al. recently published a phase II study of gemcitabine, doxorubicin and 
paclitaxel (GAT) as first line chemotherapy for MBC. The study demonstrated that the 
addition of gemcitabine to doxorubicin and paclitaxel produced clinical results using 
low doses of the three drugs. Median response duration was 16.4 months. The 
median overall-survival time was 36.4 months28. Piccart-Gebhart  et al. found that 
taxanes were significantly worse than single-agent anthracyclines in terms of PFS, 
but not in terms of response rates or survival. Taxane-based combinations were 
significantly better than anthracycline-based  combinations in terms of response rates 
and PFS, but not in terms of survival29. 
 
The present ´Arbeitsgemeinschaft Gynäkologische Onkologie´ (AGO) guidelines 
recommend for first-line cytotoxic monotherapy agents for MBC: anthracyclines, 
taxanes, vinorelbine and nab-paclitaxel. First-line polychemotherapy options include: 
anthracycline plus taxane, and paclitaxel plus capecitabine. After adjuvant application 
of anthracyclines, docetaxel plus capecitabine, taxanes plus gemcitabine and CMF 
are recommended. Cytotoxic therapy recommendations after previous application of 
taxanes and anthracyclines include: capecitabine, peg-liposomal doxorubicin, 
vinorelbine, ixabepilone plus capecitabine and gemcitabine plus vinorelbine.  
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1.3.3   IMMUNE THERAPY 
1.3.3.1 TRASTUZUMAB 
Growth factors and their receptors play an important role in the pathogenesis of 
human cancer. The human epidermal growth factor receptor-2 (HER-2) encodes for 
a transmembrane receptor glycoprotein with tyrosine kinase activity. Normal 
epithelial cells contain two copies of the HER-2 gene and express 20.000-50.000 
HER-2 receptors on the cell surface30. This receptor plays a central role in cellular 
growth. The consequence of HER-2 gene amplification is the over-expression of up 
to 2.000.000 receptors per cell (Figure 2.). This over-expression is seen in 
approximately 25-30% of all human breast cancers and is associated with clinically 
aggressive disease and a shorter survival time30,31,32. HER2 over-expression is 
determined by the immunohistochemical staining score (DAKO Hercep TestTM) and a 
fluorescence in-situ hybridisation (FISH) gene amplification analysis.  
 
In 2001 Slamon et al. found that a humanized monoclonal antibody (trastuzumab) 
(Figure 7) directed against the HER-2 receptor provided substantial clinical benefit to 
HER-2 positive metastatic breast cancer patients30. Two important phase III trials 
have evaluated the addition of trastuzumab to chemotherapy in women with HER-2 
over expressing MBC33,34. Both studies found that the combination of chemotherapy 
and trastuzumab resulted in significantly higher overall response rates with a longer 
median time to disease progression and overall survival time than with chemotherapy 
alone (resp. 25.1 to 20.3 months and 31.2 to 22.7 months). 
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Figure 7.  Functioning of the humanized monoclonal antibody trastuzumab. 
Source: www.biotech.org.cn 
 
Since May 2006 trastuzumab is approved for treatment of patients with metastatic 
breast cancer and HER2 over-expression, when at least two chemotherapy regimens 
have been given prior to the treatment. These chemotherapeutic regimens should 
include an anthracycline and a taxane, with the exception that those therapies have 
shown to be ineffective for the patient. For patients with an endocrine sensitive 
tumor, the endocrine therapy has to be shown to be ineffective or intolerated by the 
patient. In first-line therapy, trastuzumab is approved in combination with paclitaxel or 
docetaxel. 
1.4 BISPHOSPHONATES  
About 50-70% of women with metastatic breast cancer develop bone metastases 
during the course of the disease. These metastases are the source of severe pain, 
pathological fractures, hypercalcaemia and neurologic complications. Breast cancer 
bone metastases are predominantly osteolytic (50%) or mixed (40%), with only a 
small proportion (about 10%) being osteoblastic alone35. Osteoclasts account for 
bone resorption of lytic metastases, whether by direct activation through tumor cells 
or via tumor-secreted factors like cytokines. Bisphosphonates are potent inhibitors of 
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osteoclast bone resorption. The use of bisphosphonates is indicated for the treatment 
of osteoporotic disease, osteolytic bone metastases and cancer induced 
hypercalcaemia. Table 8. gives an overview of bisphosphonates in current use.  
 
Table 8.  Overview of bisphophonates in current use. 
Clodronate Bonefos®, Ostac® 
Pamidronate Aredia® 
Zoledronic acid Zometa® 
Ibandronate Bondronat® 
 
Clodronate was the first oral bisphosphonate and was investigated by Paterson et al. 
in a double-blind, placebo-controlled trial in 1993.  Clodronate showed a significant 
improvement in the reduction of hypercalcaemic events, vertebral fractures and 
vertebral deformities. A trend was seen in the reduction of pain36. In 1996 and 1998 
Hortobagyi et al. published data about Pamidronate. The infusion of 90 mg 
pamidronate every month significantly reduced the median time to first skeletal 
complication (13.0 months for the pamidronate group and 7.0 months for the placebo 
group, p<0.001). The mean pain scores and reduction of performance status were 
significantly decreased in the pamidronate group. Survival time did not differ between 
the two groups37,38.  The review by Allan Lipton describing bisphosphonate therapy 
concluded that zoledronate was as active against skeletal related events as 
pamidronate and showed better affectivity for zoledronate in preventing the need for 
radiation therapy of the bone39.  The ASCO (American Society of Clinical Oncology) 
guidelines for clinical practice (2003) recommend for women with radiographic lytic 
bone metastases, zoledronic acid (4 mg over 15 minutes every three to four weeks) 
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or pamidronate (90 mg over two hours every three to four weeks). There is 
insufficient evidence to recommend one over the other, although zoledronic acid is 
more convenient because it can be administered over a shorter period of time.  
1.5 LOCO-REGIONAL TREATMENT OPTIONS  
Loco-regional treatment has gained acceptance in the treatment of metastases in the 
last few years. For hepatic lesions of colorectal cancer, hepatic resection is a well 
accepted and effective treatment option. Liver metastases of breast cancer are 
increasingly being treated in the same manner.  Adam et al. reviewed 85 patients 
with breast cancer liver disease (BCLD) treated with hepatic resection and showed a 
median and 5-year overall survival of 32 months and 37%, compared to OS rates of 
3-15 months for BCLD treated with the standard medical therapy methods40. The 
impressive data achieved by hepatic resection may in part be explained by patient 
selection.  
The role of radiofrequency ablation (RFA) of BCLD has not yet been established. Lee 
et al. reviewed the role of hepatic resection and RFA for hepatic metastases of 
colorectal cancer. The hepatic resection group showed a significantly better 
cumulative 3-year and 5-year local recurrence free survival rate of 88.0% and 84.6%, 
compared with 53.3% and 42.6% for those in the RFA group (P=0.001).The 5-year 
OS rate was lower in the RFA group as compared with the hepatic resection group 
without statistical significance (5-year OS, 65.7% in the HR, 48.5% in the RFA group, 
P=0.227). Despite a higher local recurrence rate, RFA may be considered as a good 
therapeutic option for patients who are considered unsuitable for conventional 
surgical treatment41. Hoffmann et al. demonstrated that SIRT (selective internal 
radiation therapy) followed by RFA of the liver, for patients with hepatic lesion of 
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different tumor entities (16 of 46 patients had MBC), was successful in terms of 
complete ablation. In selected patients radio-embolization is able to downstage liver 
metastases to an extent making subsequent RFA effective thereby increasing the 
number of patients with a “complete response” after minimally invasive therapy42.  
The role of surgical resection of pulmonary metastases has to be defined. Welter et 
al. showed in a retrospective analysis that surgical resection of pulmonary 
metastases was associated with a OS time of 32 months, indicating that this 
approach might be of benefit for a small proportion of patients with resectable, 
singular pulmonary metastases43.  
 
1.6  SURVIVAL OF METASTATIC BREAST CANCER 
Overall survival rates of women with MBC have been the subject of intense 
investigation. The effectiveness of chemotherapy in improving the outcome of MBC 
patients has been demonstrated both in individual studies and in meta-analyses of 
published randomized trials. Schlesinger-Raab et al. recently published an 
epidemiologic research of survival rates based on data from the tumor registry centre 
in Munich, Germany, for a study period of 20 years (1978-2002)44. In summary, this 
study found that survival after metastases was related to age, grade, receptor status 
and survival time without metastasis. However, the outcomes were not influenced by 
time of diagnosis of the primary tumor or of the metastases or the hospital where the 
treatment occurred, see Figure 1. 
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Figure 1. Survival after diagnosis of first metastasis for four time intervals, (n = 5546). 
 
 
Source: Deutsches ÄrzteblattJg. 102Heft 407. Oktober 2005 
 
On the contrary, Giordano et al. found in 2003 that survival of women with recurrent 
breast cancer has been improving over the past decades. The median survival 
duration was 15 months, 17 months, 22 months, 27 months, and 58 months in the 
groups who developed recurrent disease during 1974-1979, 1980-1984, 1985-1989, 
1990-1994 and 1995-2000. However, the more recent groups were confounded by 
more favourable profiles of prognostic factors45. Gennari et al. found as well a 
significant increase in overall-survival in recent cohorts. Median overall-survival was 
18 months in 1983-1986 and 23.6 months in 1998-2001 (p for heterogeneity 
<0.0001)6.  As described in chapter 1.3.3, Slamon et al. in 2001 found significant 
survival benefits in HER2-positive metastatic breast cancer patients treated with a 
combination of chemotherapy (anthracycline/ cyclophosphamide or paclitaxel) and 
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trastuzumab33. O’Shaughnessy reviewed in 2005 how the introduction of modern 
chemotherapeutic agents such as taxanes has helped improve survival time on the 
order of 3 months. Targeted biologic agents like trastuzumab in combination with 
traditional chemotherapeutics showed impressive response and survival benefits with 
improvements in overall survival ranging from 4 to 8 months1.  
 
1.7  STUDY AIMS  
First-line studies for metastatic breast cancer have progression free survival (PFS) as 
primary endpoint. Overall survival is mostly reported as a secondary endpoint. As the 
treatment of MBC consists of many different agents over time, it is difficult to find out 
what the present overall survival time of MBC really is. There is a lack of studies 
describing whole treatment regimens during course of disease. Many published 
reports describe overall survival rates of MBC in time cohorts, end before 2000 or 
continue to 2002. As the administration of newer and more active chemotherapeutic 
agents (taxanes) and the targeted biologic agents like trastuzumab have been a part 
of treatment regimens since 2000, some of these reported time cohorts might not yet 
show the real benefits arising from use of these agents. Anecdotal clinical 
observations of specialized oncologists indicate that the overall survival of patients 
with MBC is improving over time. This study was started to investigate the current 
overall survival rates of women with MBC in a small clinical setting using all of the 
clinical date available out of the medical chart.  
 
The aim of this retrospective analysis is to describe and define current overall 
survival rates of women with metastatic breast cancer, to whom treatment has been 
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given in the outpatient clinic of the oncology department of the university hospital 
Munich, Großhadern, between 2000 and the end of 2005, with respect to: 
 patient characteristics  
 tumour size, nodal status, grading, hormonal- and HER2 receptor state 
 adjuvant chemotherapy and endocrine therapy given 
 site of metastases and number of metastatic sites  
 palliative systemic treatment, e.g. chemotherapy, endocrine treatment, 
targeted therapies and bisphosphonates given.   
 loco-regional treatment given for metastatic lesions 
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2.  MATERIALS AND METHODS 
2.1  STUDY FOCUS 
Subjects for this retrospective case study were women who came for treatment of 
metastatic breast cancer (MBC) to the outpatient clinic of the oncology department of 
the university hospital Munich Großhadern. Patients’ recruitment was based on 
electronic review of the diagnostic database of the medical oncology department. 
Criteria for review were women with metastatic breast cancer treated in the 
outpatient clinic, between January 2000 and December 2005. The electronic review 
showed 669 women with “metastatic breast cancer” in the medical oncology 
department during this time period. Many patients came to our outpatient clinic for a 
second opinion concerning treatment options or for a short treatment of a critical 
condition. Other patients only had one or two therapies in our clinic and further 
treatment was continued somewhere else. All these patients were not included in the 
analyses. The study only included the women to whom the entire anti-cancer 
treatment was given in our outpatient clinic. In total the study identified 232 cases of 
women with MBC who satisfied the criteria. 
 
2.2  STUDY DESIGN 
The study employed a retrospective design, using all the medical documentation 
available for each patient who satisfied the entry criteria and was eligible for inclusion 
in the study.  
Data that were collected about each case included: 
 Date of birth  
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 Date of primary diagnosis  
 Primary tumour size, nodal state, grading, hormonal receptor state and HER2- 
receptor state at first diagnosis  
 Date of first metastasis, site of first metastasis.  
 Other sites of metastases developed in course of disease and dates of 
diagnosis of these metastases    
 Treatment given adjuvant and palliative (e.g. surgery, radiotherapy, loco-
regional treatment, endocrine treatment, chemotherapy, bisphosphonates and 
targeted therapies given). 
 Last date of a consultation with the medical oncologist in the university 
hospital (Follow-up) 
 Date of death 
 
Discrepancies in patient records related to diagnosis and treatment given were 
discussed with the nurses and medical oncologists of the department. Survival data 
were obtained from the medical chart. When information about the patients’ deaths 
was unclear or not well documented, these patients were discussed with their 
general practitioner or with their family.  
 
Hormonal receptor status was documented for both estrogen- and progestarone 
receptors, using the immune reactive score (Remelle score). Positive receptor stage 
was given to a score of 2 and more. 
 
HER2 over-expression was determined by the immunohistochemical staining score 
(DAKO Hercep TestTM) and a fluorescence in-situ hybridisation (FISH) gene 
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amplification analysis and was reported as positive after a test result of DAKO 3+ and 
DAKO 2+ together with a positive FISH test result. 
 
Patient characteristics and tumour characteristics were verified retrospectively in the 
medical chart. Information regarding year of diagnosis, age, site of metastases, and 
medical treatments was also obtained directly from the medical chart. When no 
information describing tumour characteristics, estrogen and progestarone receptor 
status and HER2 receptor status was available in the medical chart, the missing data 
were verified with the tumor registry of Munich and with the department of pathology 
of the university hospital Munich, Großhadern. Missing data after this verification 
were coded as unknown.  
 
A differentiation was made between visceral and non-visceral metastases. Patients 
presenting with soft tissue/lymph node involvement, bone involvement and/or 
cutaneous involvement at the exclusion of any other site were classified as having 
non-visceral metastases. Numbers of metastatic sites in course of treatment were 
analysed. One site was defined as one organ involved.  A differentiation was also 
made between local-recurrence (e.g. local lymph node metastasis) and distant 
metastases.  
 
Systemic treatment agents were analysed and a differentiation was made in; 
adjuvant chemotherapy and hormone therapy given, numbers of sequences of 
palliative chemotherapy given, numbers of sequences of palliative endocrine therapy 
given and the percentage of aromatase inhibitors given within, and bisphosphonate 
therapy given in course of treatment. Finally the total number of sequences of 
systemic treatments provided in palliative care was calculated and analysed. One 
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sequence of therapy (chemotherapeutical/endocrine therapy) was defined as one 
drug being given. When one drug was being given twice with other therapies being 
given in between, this drug was calculated as an extra sequence.   
 
2.3  STATISTICAL ANALYSIS 
Statistical analyses were performed using Statistical Package for the Social Sciences 
(SPSS version 16.0). Overall survival was measured from the initial diagnosis of 
systemic metastatic disease until death from any cause (intent-to-treat) or last visit to 
the medical oncology department.  
 
Probability of survival was estimated by Kaplan-Meier analysis and compared using 
the log-rank test. Differences were considered statistically significant when p<0.05. A 
multivariate logistic regression model was used to calculate hazard ratios and 95 
percent confidence intervals to investigate the relation between overall survival of 
metastatic breast cancer and the factors that were statistically significant in the 
univariate analysis. The proportional hazard assumption was tested by the global test 
of Grambsch and Therneau. 
 
This study was performed as a retrospective analysis. All endpoints evaluated in this 
analysis are explorative in nature. Results obtained can therefore only serve the 
purpose of hypothesis-generation.  
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3.  RESULTS                                                                                                        
3.1  PATIENT CHARACTERISTICS  
 
In total, the study identified 232 cases of women with MBC who received their entire 
anti-cancer treatment in our outpatient clinic. Table 9 shows a summary of patient 
characteristics. Patients were diagnosed with primary breast cancer at a median age 
of 49 years (range: 25-84) and 53 years (range: 27-87) for the diagnosis of 
metastatic disease. The median time of follow-up of the living study participants was 
35.5 months. The greater part (76.2%) were diagnosed with a tumor smaller than 5 
cm (T1 and T2 stage of tumor at diagnosis), with 14 % having a tumor of 5 cm at 
least at diagnosis. Approximately a quarter had a node negative tumor (n=64, 
27.6%). 
Of the 232 women who were analysed in this investigation, 32 (14.7%) had 
synchronous metastasis at the time of diagnosis. The majority of patients with node 
positive disease (n=142) received adjuvant chemotherapy 71.9% (n=102). The 
administration of anthracyclines (31.0%), the combination of CMF (30.3%), and the 
combination of anthracyclines and taxanes (14.8%), were the most frequently given 
adjuvant chemotherapies. Adjuvant endocrine therapy was administered to 42.2% of 
all patients. Invasive surgery was performed on 44.4% of the patients, they received 
a mastectomy. Almost half of the patients received adjuvant radiotherapy (46.2%). 
The median time between primary diagnosis and metastatic disease was 35.5 
months (range 0-18 yrs). Hormone receptor (HR) positive tumours were found in 174 
patients (75%).  Subdivided, 70% of the women (n=163) had an estrogen-receptor 
positive tumor and 65% (n=151) were progestarone-receptor positive. An over-
expression of HER2 was detected in one third of patients (n=79, 34%). A triple 
negative tumor was diagnosed in 15 patients (6.5%).  
34 
 
Table 9.  Patient characteristics of women with metastatic breast cancer. 
 
 
 
 
Patient characteristics 
 
 
All patients; n 
(%) 
 
 
Patients 
 
232 (100) 
 
Median age at diagnosis of primary lesion 
[range;years] 
 
49   [25-84] 
 
Median age at diagnosis of metastases 
[range;years] 
 
53   [27-87] 
 
Median time between primary lesion and first 
metastasis [range;months]  
 
Median time of follow up of metastatic 
disease [range;months] 
 
35.5 [0-24] 
 
 
33    [0-281] 
 
Size of primary lesion  
     Tis 
     T1 
     T2 
     T3 
     T4 
     Unknown 
 
 
 2    (0.8) 
90   (38.8) 
85   (36.6) 
18   (7.8) 
15   (6.5) 
22   (9.5) 
 
Nodal status of primary lesion 
     N0 
     N1 
     N2 
     N3 
     Unknown 
 
 
64   (27.6) 
122 (52.6) 
16   (6.9) 
4     (1.7) 
26   (11.2) 
 
Metastases at time of primary lesion 
     M0 
     M1 
 
 
198  (85.3) 
34    (14.7) 
 
Grading of primary lesion 
     G1 
     G2 
     G3 
     Unknown 
 
 
7     ( 3.0) 
99   (42.7) 
113 (48.7) 
13   ( 5.6) 
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Estrogen receptor status  
      ER positive 
      ER negative 
     Unknown 
 
Progestarone receptor status  
      PR positive 
      PR negative 
     Unknown 
 
HER2 receptor status  
     HER2 positive 
a
 
     HER2 negative  
     Unknown 
 
Triple negative 
e
 
 
Site of first metastasis 
b
 
     Liver 
     Lung 
     Bone 
     Brain 
     Soft tissue 
c
 
     Other 
d
 
 
Non-Visceral and Visceral metastasis        
     non-Visceral 
     Visceral 
 
Number of metastatic sites in the course  
of treatment 
     1 
     2 
     ≥3 
 
Surgery of primary tumour 
     Lumpectomy 
     Quadrantectomy  
     Mastectomy 
     Other 
     No Surgery 
 
Adjuvant radiotherapy of primary tumour 
      Yes 
      No 
 
Adjuvant treatment of primary tumour: 
  
  Chemotherapy of N positive patients
 f
 
     Anthracyclines 
     CMF 
     Anthracyclines + Taxanes  
     Taxanes 
     Other regimens 
     No Adj. Chemotherapy 
      
  Endocrine treatment of all patients 
      
 
 
 
163 (70.3) 
59   (25.4) 
10   ( 4.3) 
 
 
151 (65.1) 
72   (31.0) 
9       (3.9) 
 
 
79   (34.1) 
119 (51.3) 
34   (14.6) 
 
15     (6.5) 
 
 
72  (22.3)  
60  (18.6) 
88  (27.2) 
10    (3.1)      
80  (24.8) 
13    (4.0) 
 
 
114 (49.1) 
118 (50.9) 
 
 
 
83  (35.8) 
82  (35.3) 
67  (28.9) 
 
 
14     (6.0) 
47   (20.3) 
103 (44.4) 
45   (19.4) 
23     (9.9) 
 
 
109 (46.2) 
125 (53.8) 
 
 
   
 
 44 (31.0) 
 43 (30.3) 
 21 (14.8) 
   1 (1.4) 
   8 (5.6) 
 40 (28.2) 
   
 98 (42.2) 
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a  
HER2 positive = DAKO 2+ with FISH+ or DAKO 3+ 
b
 Patients were mentioned twice or more because of two or more metastatic sites 
(sum>100%). 
c
 Includes axillary and supraclaviculary lymph nodes and local recurrence.  
d
 Includes skin, orbita, ovarial, retina, pericard, thyroid, kidney and peritoneal 
metastases. 
e
 Triple negative are patients with a negative estrogen receptor, a negative 
progestarone receptor and a negative HER2 receptor. 
f
 Patients were mentioned twice because of combination therapies (sum>100%). 
 
 
Regarding metastatic disease, visceral (solid organ) involvement was diagnosed in 
118 patients (50.9%). The site of first metastases was (in descending order): Bone- 
(27.2%), soft tissue including lymph-nodes and skin- (24.8%), liver- (22.3%), lung- 
(18.6%), other (4.0%), and brain metastases (3.1%). 
 
Considering the course of disease, almost one third (28.9%) developed more than 
three different sites of metastasis, whereas 70% developed two different sites or less. 
Patient characteristics of the whole study population are presented in Table 9. 
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3.2 SURVIVAL 
3.2.1 OVERALL SURVIVAL 
At the time of analysis, 126 women (60%) out of 232 had died because of metastatic 
disease. The median overall survival (OS) for all women included in this research 
was 44 months [95% CI; 39-49 months]. These results are shown in the Kaplan 
Meyer survival plot of the 232 women with MBC included in this analysis (Figure 8).  
 
Figure 8.  Kaplan-Meier estimate of OS of all patients. 
 
No. at Risk:       
All patients      232       171             86                   46                 31                     
 
 
 
 
median 44 months 
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3.2.2.  TUMOR CHARACTERISTICS AND SURVIVAL 
3.2.2.1 TUMOR SIZE 
Considering tumour size at primary diagnosis, women with tumours between 2 and 5 
cm (pT2) had the longest median survival of 53 months [95% CI 37-69 months]. 
Women with pT3 and pT4 tumours at diagnosis had a median survival of 34 months, 
see Figure 9. 
 
Figure 9.  Kaplan-Meier estimate of overall survival by T stage of primary tumor. 
 
No. at Risk: 
T1  88        66  30       14  9 
T2  84        66  36       23  15 
T3  16        11  5         2   1 
T4  14        11  5         3   2 
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3.2.2.2 NODAL STAGE  
Of all patients 65 women had node negative tumours. With 57 months [95% CI 41-73 
months], these women had better survival rates than those with node-positive 
tumours (n=141). They showed a median OS of 38 months [95% CI 32-44 months]. 
The distribution of overall survival rates of node-positive vs. node-negative patients 
reached the level of significance with p=0.037 (Figure 10A).  
 
Figure 10A.  Kaplan-Meier estimate of overall-survival by N-stage of primary tumor. 
 
No. at Risk: 
N-negative           65   54            32            17          11 
N-positive           141   96            41            22          15 
 
 
 
 
 
 
 
 
P=0.11 
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3.2.2.3 M-STAGE OF DISEASE AT DIAGNOSIS 
Thirty-four women (14.7%) had synchronous metastases at time of primary 
diagnosis. At time of analyses 18 women (53%) died. Median age at time of 
diagnosis of these women was 52 years. Of these women 27 (79.4%) had hormone 
receptor positive disease.  A visceral metastases was diagnosed in 12 cases (35.3%) 
and 10 women (29.4%) had primary bone metastases. The distribution of overall 
survival rates of women with synchronous metastases (median OS of 81 months 
[95% CI 15-146]) versus women with metachronous metastases (median OS of 43 
months [95% CI 38-47])  did not reach the level of significance  (p>0.05) (Figure 10B) 
 
Figure 10B.  Kaplan-Meier estimate of overall-survival by M1-stage of primary tumor. 
 
No. at Risk: 
M0             195 146   78      36        24   
M1               33  24   12       9          5  
 
 
P>0.05 
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3.2.2.4 GRADING 
Women with grade 3 tumours (n=113] had a median survival of 40 months [95% CI 
33-47 months], compared to a median overall survival of 46 months [95% CI 36-56 
months] for women with a grade 2 tumour. The 7 women with a grade 1 tumour at 
diagnosis all lived at the time of analysis. Therefore, we cannot report the survival 
rates for these women (Figure 11).  
 
Figure 11.  Kaplan-Meier of estimate of OS and grade of tumour at diagnosis. 
 
 
No. at Risk: 
G1             7        7                7       7  7    
G2           99      77              39     18  14 
G3         113      78              37     22  11 
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3.2.2.5 HORMONE RECEPTOR 
In total 49 patients were diagnosed with a hormone receptor negative tumor. 
Hormone receptor positive tumours were seen in 174 patients. Of nine patients the 
HR status was unknown. Women with HR-positive tumours showed a median 
survival of 46 months [95% CI 38-54 months], whereas the survival of those with HR-
negative tumours was 34 months [95% CI 18-50 months]. Despite a median survival 
difference of 12 months, this difference does not reach the level of significance 
(p>0.05) (Figure 12). 
 
Figure 12.  Kaplan-Meier estimate of OS by HR. 
 
 
No. at Risk: 
HR-    174   132          64   35         23 
Hr+      49     31            7     8           5 
 
 
p=0.16 
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Subdivision of hormone receptor-stage of disease showed a median survival of 37 
months [95% CI 28-46] for estrogen negative disease (n=59), compared to 46 
months [95% CI 35-57] for women with an estrogen positive tumour (n=164, 
p=0.091) (Figure 13) . Statistical significance was shown in median OS and 
progestarone receptor (PgR) stage of the tumour with a median OS of 40 months 
[95% CI 29-51] for PgR negative- (n= 72) and 44 months [95% CI 34-54] for PgR 
positive tumours (n=151) (p=0.044) (Figure 14). 
 
Figure 13.  Kaplan-Meier estimate of OS by estrogen receptor stage of disease. 
 
 
No. at Risk: 
ER-              57     38            15    8          5 
ER+            163   125            64                 36        23 
 
 
p=0.09 
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Figure 14.  Kaplan-Meier estimate of OS by progestarone receptor stage of 
disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No. at Risk: 
PR-         71    49        25  14       9 
PR+        150  114        54                 29     19 
 
 
 
 
 
 
 
 
 
 
p=0.04 
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When HER2 over expression is considered, median overall survival did not 
demonstrate any significant difference, with 42 months [95% CI 32-52] for HER2 
negative (n=119) and 41 months [95% CI 37-51] for HER2 positive tumours (n=79).  
Looking at the group of women with a HER2 positive tumour and the ones who 
received trastuzumab (n=61) as medication, a median OS of 44 months [95% 36-52] 
was shown, compared to 30 months [95% CI 18-42] for the ones who did not receive 
trastuzumab (n=18). Of the 79 patients with HER2 positive tumours, 61 received 
trastuzumab (77.2%) (Figure 15) 
 
Figure 15.  Kaplan-Meier estimate of OS by trastuzumab therapy for HER2 positive 
tumours.  
 
No. at Risk:     
T-             17    16           6  2       1 
T+             58     45               20  8       4 
 
p=0.26 
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Triple negative disease was clearly related to a negative survival outcome. We 
identified 15 patients (6.5%) with triple negative disease. These 15 women had a 
median OS of 16 months [95% CI 7-25] (p=0.018). See figure 16 for the overall 
survival curve of these women.  
 
Figure 16.  Kaplan-Meier estimate of OS by triple negative disease. 
 
No. at Risk: 
Other            217    163           83    46        31 
Triple-              15        7                  1      0          0 
 
 
 
 
 
 
 
 
 
p=0.02 
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3.2.2.6 AGE AT DIAGNOSIS  
A survival analysis was also made for the factor “age at diagnosis of metastatic 
disease”. This analysis was made in different age groups; >50, 50-69 and ≥ 70 years. 
Median age at diagnosis of metastatic disease was 53 years [range: 27-87]. Eighty-
two women (35%) were younger than 50 years, 123 women (53%) were between 50 
and 69 years and 27 women (12%) were ≥ 70 years at time of diagnosis. The median 
OS rates of three groups with ascending age category are 40 [95% CI 21-58], 46 
[95% CI 38-54] and 44 months [95% CI 38-47] (Figure 17). 
 
Figure 17.  Kaplan-Meier estimate of OS by age at diagnosis 
 
No. at Risk: 
<50         79       55    29         17  13             
50-69        122       94    50        25  14               
≥70         25        21    10          2                      1 
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3.2.3. COURSE OF DISEASE AND SURVIVAL 
 
To evaluate the influence of course of disease on survival, the number of metastatic 
sites developed, local recurrence versus distant relapse, the presence of visceral 
metastasis (recorded as yes or no), and single lung and single liver metastasis 
specifically were analysed. 
 
3.2.3.1 NUMBER OF METASTATIC SITES   
 
This study considered 122 women who developed one metastatic site during the 
course of disease. These patients had a median OS of 60 months [95% CI 33-87]. 
Two metastatic sites were developed by 78 women and this group had a median OS 
of 37 months [95% CI 32-42]. Three or more sites in course of disease were shown 
by 32 women (median OS of 36 months, 96% CI 18-54). Figure 18 shows the 
survival curves for these patients.  
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Figure 18. Kaplan-Meier estimate of OS by number of metastatic sites developed 
during the course of disease. 
 
No. at Risk: 
1         122  92         48      26       18 
2           78  59         25      14         9 
3>           32  18         11        6         4 
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3.2.3.2 LOCAL RECURRENCE AND DISTANT METASTASES 
 
This study also differentiated between women who developed a local recurrence 
(n=22) (e.g. local lymph node recurrence) and women who had distant metastases 
during the course of disease.  The group of women who developed a local 
recurrence did not reach the 50% cumulative survival line; as a consequence a 
median OS rate could not be estimated. The survival curve of these women showed 
a very good prognosis until study end. The women who developed distant 
metastases (n=210) showed an OS of 39 months [95% CI 34-44]. This distribution 
reached the level of significance (P < 0.01) (Figure 19). 
 
Figure 19.  Kaplan-Meier estimate of OS and distant metastases versus local 
recurrence of disease. 
 
 
No. at Risk: 
Local             15     15          15  9         5 
Distant           209   148               69  38       26 
 
p<0.01 
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3.2.3.3 VISCERAL METASTASIS 
The negative prognostic outcome related to visceral involvement of metastatic 
disease was confirmed by the OS of this group of women in this study. Visceral 
organ involvement was documented for 118 women and showed a median OS of 34 
months, compared to a median OS of 57 months for no visceral involvement in 114 
women (P=0.001) (Figure 20). 
  
 
Figure 20.  Kaplan-Meier estimate of OS by visceral or non-visceral metastases. 
 
 
No. at Risk: 
No visc. met.      113 93        59  37      25 
Visc. met.           116 80            25  12        6 
 
 
 
 
 
 
p<0.01 
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3.2.3.4 SINGULAR LUNG AND LIVER METASTASIS 
 
As loco-regional treatment options of metastatic breast cancer are improving (e.g. 
surgical resection, RFA), women with these metastases were analysed specifically 
regarding survival. 
 
Singular lung metastasis was shown in 24 women. Of this group, 9 women died 
because of MBC. The median OS rate for this group was 56 months (95% CI 23-89).  
Singular hepatic lesions were shown in 31 women; of these, 17 women died as a 
result of MBC. The median OS for this group of women was 50 months (95%CI 31-
69) (Figure 21). 
 
Figure 21. Kaplan-Meier estimate of OS by single liver and single lung metastases. 
 
No. at Risk: 
Others         177  127        74      41       28 
Liver           31  22        11        4         3 
Lung           24  24          8          3          1 
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Loco-regional treatments for hepatic- and pulmonal metastases were given to 31 
patients (13 patients received radiofrequency ablation (RFA),  laser-induced thermo 
therapy (LITT) was given to three patients, one patient was treated with 
chemoembolisation of the liver, partial liver- or lung resection was performed on three 
and 11 patients). 
 
3.2.3.5 BONE METASTASES 
Of all the patients studied, 91 women (39.2%) developed bone metastases in the 
course of disease. Treatment with bisphosphonates was given to 57 patients (63%) 
while the other patients received systemic treatment with endocrine-, targeted and/or 
chemotherapy regimens with or without radiotherapy. Bisphosphonate therapy was 
also given to 28 patients without bone metastases. Reasons for these women to 
receive a bisphosphonate therapy could be that they received an endocrine 
treatment (aromatase inhibitors) which led to osteoporosis and/or because patients 
were susceptible for osteoporosis because of age.  
 
Hormonal-ablative therapies for breast cancer can cause marked and rapid 
reductions in circulating estrogen levels, resulting in significant effects on bone 
metabolism and cancer treatment-induced bone loss (CTIBL). Bisphosphonates have 
the potential to delay or prevent CTIBL in patients receiving hormonal therapies46. 
Among all patients, 40 women had only bone metastases. Of these patients 85% 
received bisphosphonate treatment.  
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The median OS of the women bone metastases was 46 months (Figure 22).  
 
Figure 22. Kaplan-Meier estimate of OS by bone metastases. 
 
No. at Risk: 
Bone           40  26        16      10       8 
 
 
 
 
 
 
 
median 46 months 
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3.3  UNI- AND MULTIVARIATE ANALYSIS  
 
A univariate analysis was made to investigate the relation between the prognostic 
factors investigated in this study and the overall survival rates of MBC (Table 10). A 
P- value of global test was calculated for categorical variables.  
 
Table 10. Univariate analysis of prognostic factors for overall survival. 
 
 
 
Overall Survival 
 
Characteristics Hazard 
Ratio 
95% CI P P Value of 
global test for 
categorical 
variables 
Age at metastatic disease 1.00 0.98-1.01 0.60  
T Stage 
 T1 
T2 
T3 
T4 
 
5.16 
0.86 
0.71 
1.54 
 
1.10-23.58 
0.44-1.66 
0.37-1.37 
0.68-3.46 
 
0.04 
0.65 
0.31 
0.30 
0.16 
N Stage 
N1 
N2 
N3 
 
1.28 
1.98 
1.97 
 
0.18-9.37 
0.27-14.23 
0.25-15.56 
 
0.81 
0.50 
0.52 
0.18 
M Stage 0.98 0.60-1.62 0.94  
Grading 
G1 
G2 
G3 
 
0.00 
0.84 
- 
 
0.00-8.55 
0.59-1.19 
- 
 
0.95 
0.32 
- 
6.11 
Estrogen receptor 0.72 0.49-1.06 0.09  
Progestarone receptor 0.70 0.49-1.06 0.09  
Hormone receptor 0.73 0.49-1.09 0.12  
Her2 receptor 1.25 0.85-1.83 0.26  
Triple negative disease 2.22 1.12-4.40 0.02  
Number of metastatic sites 
1 
2 
≥3 
 
0.61 
1.09 
- 
 
0.37-1.01 
0.66-1.78 
 
0.06 
0.75 
0.01 
Visceral metastases 1.76 1.24-2.50 <0.01  
Distant metastases 3.68 1.50-9.02 <0.01  
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David W. Hosner and Stanley Lemeshow wrote in Chapter 5 of their book about 
“applied survival analysis” that all significant variables at the 20-25 percent level 
(p<0.2) in the bivariate analysis should be selected for the multivariate analysis 68.  
 
For this study the covariates T-Stage, N-Stage, estrogen receptor, progesterone 
receptor, hormone receptor, triple negative disease, number of metastatic sites, 
visceral metastases and distant metastases were therefore part of the multivariate 
logistic regression model. To avoid the problem of multicollinearity, this study took 
triple negative disease (most significant associated with OS, p=0.02) as a factor for 
the multivariate analyses and left estrogen receptor, progesterone receptor and 
hormone receptor out of the analysis. The final model included 199 patients. The 
proportional hazards assumption of the Cox regression model was reasonably 
fulfilled (p=0.623).  
 
In the multivariable model T-stage (P-value of global test: <0.01), triple negative 
disease (p=0.02), number of metastatic sites (p=0.02) and visceral metastasis 
(p<0.01) were statistically significant associated with worse overall survival after 
adjusting for all factors in the table (Table 11).  
 
 
 
 
 
 
 
 
57 
 
Table 11. Multivariate analysis for overall survival.  
 
 
 
Overall Survival 
 
Characteristics Hazard 
Ratio 
95% CI P P Value of 
global test for 
categorical 
variables 
T Stage 
T1 
T2 
T3 
T4 
 
6.96 
1.10 
0.70 
2.16 
 
1.35-35.91 
0.52-2.31 
0.33-1.49 
0.86-5.42 
 
0.02 
0.82 
0.35 
0.10 
<0.01 
N Stage 
N1 
N2 
N3 
 
2.83 
3.81 
5.31 
 
0.37-21.37 
0.51-28.34 
0.65-43.61 
 
0.31 
0.19 
0.12 
0.19 
Triple negative disease 2.53 1.18-5.41 0.02  
Visceral metastasis 2.10 1.34-3.18 <0.01  
Number of metastatic sites 
1 
2 
≥3 
 
0.95 
1.07 
- 
 
0.53- 1.71 
0.95-3.07 
- 
 
0.86 
0.08 
0.02 
Distant metastasis  2.12 0.73-6.18 0.17  
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3.4  CHARACTERISTICS OF PALLIATIVE CHEMOTHERAPY 
3.4.1 OVERVIEW OF PALLIATIVE CHEMOTHERAPY TREATMENT 
 
Following adjuvant treatment (see Table 9.), anthracyclines and taxanes were the 
most frequently given first-line palliative treatments, followed by capecitabine, 
navelbine and CMF. As second-line treatment, most patients received capecitabine, 
or gemcitabine in combination with cisplatin, or navelbine. As third-line treatment, 
most patients were treated with taxanes, capecitabine and other substances (e.g. 
bendamustin, mitoxantrone). Table 12 and Figure 23 give an overview of 1st, 2nd and 
3rd-line cytostatic treatment of metastatic disease.  
 
Table 12.  Overview of chemotherapy given in palliative intent.   
 
Palliative Treatment 
 
First-line 
(n) 
 
Second-line 
(n) 
 
Third-line  
(n) 
Anthracyclines 12 3 0 
Anthracyclines and Taxanes 54 1 1 
CMF 16 0 7 
Taxanes 19 8 20 
Capecitabine 19 24 20 
Gemcitabine/Cisplatin 7 19 17 
Navelbine 18 10 17 
Others 23 14 30 
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Figures 23.  Overview of the palliative regimens given to the patients (n) 
 
 
Figure 22 analyzed together with the adjuvant chemotherapy given, shows that most 
of the women received anthracycline and taxane treatment in course of disease. 
Capecitabine, navelbine, gemcitabine and cisplatin were also used frequently in the 
treatment of MBC.  
 
 
3.4.2 SEQUENCES OF PALLIATIVE CHEMOTHERAPY TREATMENT AND SURVIVAL 
 
Data regarding systemic treatment of the women with MBC were used to calculate 
the total number of chemotherapy-sequences given to all patients during the course 
of treatment.  
Of all women with MBC, 88.4% received chemotherapeutic therapy regimens.  One 
to three sequences were given to 53.4%. Four to six sequences of treatment were 
given to 22.1% of all patients and 12.9% of all patients received more than 6 
treatment sequences in the course of treatment for MBC (Figure 24). 
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Figure 24. Number of sequences of palliative chemotherapy given to the patients 
(% of all patients).  
 
 
 
 
To see the effects of the step by step escalation of all the treatment modalities given 
in course of disease on survival, a Kaplan-Meier analysis was made for this factor 
(Figure 25). The survival-analysis showed the subgroup of women (blue line) who did 
not receive any chemotherapy treatment with an improved prognosis. These women 
had either HR-positive tumors and were well treated with endocrine therapy, had 
bone metastasis and were treated with bisphosphonates or had a loco-regional 
treatment (e.g. resection of lymph node recurrence and radiation therapy). Women 
with 1-3 sequential chemotherapies being given had a median OS of 40 [95% CI 32-
48] months, patients being treated with 4-6 sequential chemotherapies showed an 
OS of 41 months [95% CI 32-50] and patients treated with more than 6 sequential 
palliative chemotherapies in the course of disease had a median OS of 47 months 
[95% CI 40-54].  
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Figure 25. Kaplan-Meier estimate of OS and sequential palliative chemotherapy 
given.  
No. at Risk: 
0             27 20        13        7          3 
1-3           124 80        35         22        17 
4-6             51 41                   20       10          5 
>6             30 26           16    7          6   
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3.5 CHARACTERISTICS OF ENDOCRINE TREATMENT AND SURVIVAL  
Data about endocrine treatment was also used to calculate the endocrine sequences 
given in the course of metastatic disease.  Of the 174 women with HR-positive 
disease 102 women (58.6%) received 1-2 hormone substances for MBC. Sixty-five 
women (37.4%) were treated with 3-4 different endocrine treatment modalities and 4 
women received 5-6 (2.3%) endocrine agents in the course of disease. No endocrine 
therapy was given to 3 of the endocrine sensitive patients (1.7%).  
 
To evaluate the influence of new endocrine agents in the treatment of MBC, this 
study specifically looked at the percentage of aromatase inhibitors given. In the group 
of women treated with 1-2 endocrine agents (n=102), 53% of these endocrine 
treatments were aromatase inhibitors. In the group of patients treated with 3-4 
endocrine sequences (n=65) and 5-6 (n=4), 53% and 33% of these sequences were 
aromatase inhibitors (Figure 26). These data show that the application of aromatase 
inhibitors is well incorporated in the endocrine treatment in our study population. 
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Figure 26.  Overview of the endocrine sequences applied in endocrine sensitive 
patients (%), with percentage of aromatase inhibitors within each group. 
 
 
 
 
 
To evaluate the influence of endocrine therapy modifications during MBC treatment 
on overall survival, a Kaplan Meier analysis was made for all the women (n=232). 
Differentiation was made in the frequency of endocrine treatment sequences; no 
endocrine treatment, 1-2 sequences, 3-4 sequences and 5-6 sequences (Figure 27). 
Women treated with 1-2, 3-4 and 5-6 had a median OS of 46 [95% CI 38-54], 57 
months [95% CI 15-98] and 74 months. Of the group of women who did not receive 
any endocrine substances (n=61), 49 women had HR-negative disease (n=49) and 
had a worse prognosis from the beginning. The other 12 patients had an unknown 
HR-status, or were women with HR-positive disease who did not receive any 
endocrine therapy. They showed a median OS of 28 months [95% CI 19-37]. 
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Figure 27. Kaplan-Meier estimate of OS by sequential endocrine therapy given.  
 
 
No. at Risk: 
0         61  33      13            8    5 
1-2       102  77      36          18  10  
3-4         65  57      34          18  15 
5-6             4    4        4            4    1  
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3.6 SYSTEMIC TREATMENT AND SURVIVAL  
An analysis was also conducted for all treatment substances given; including 
chemotherapy, endocrine therapy, targeted therapy, and bisphosphonate treatment. 
Of the women in this study, 44.8% (n=104) received up to 4 therapy sequences, 37.5 
% (n=87) received up to 8 sequences and 17.7% (n=41) received more than 8 
treatment sequences for MBC (Table 13). Most of the women received more than 5 
therapy sequences during the course of disease (55.2%).  
 
Table 13.  Overview of all therapy sequences given in course of disease    
Total treatment sequences Percentage (n) 
1-4 sequences  44.8% (104) 
5-8 sequences  37.5% (87) 
> 8 sequences  17.7% (41) 
 
 
A Kaplan-Meier survival analysis was made for this factor (Figure 28). Women with a 
treatment of 4 or less substances had a median OS of 40 months [95% CI 34-46], 
followed by 43 months [95% CI 31-54] for women treated with 5 to 8 therapies and 
54 months [95% CI 41-67] for the women treated with more than 8 therapies.  
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Figure 28. Kaplan-Meier estimate of OS by all therapies given in course of 
treatment 
 
No. at Risk: 
<4         104  66         27  17      9 
4-8           87  65         33  16    12 
>8           41  38         27  13    10 
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4. DISCUSSION 
4.1 GENERAL OVERVIEW 
As breast cancer is the most common type of cancer in women and has an 
enormous impact on society, socially and economically, new and better treatment 
modalities are in continuous development. Advances have been made in the 
management of primary breast cancer by the introduction of screening methods, by 
better and less invasive surgical options followed by postoperative radiotherapy, by 
neo-adjuvant chemotherapy schedules for larger primary or multilocal tumours, and 
by better adjuvant hormonal- and chemotherapy options. In the treatment of 
metastatic breast cancer improvement is not only seen in supportive care as 
expressed by the wide use of bisphosphonates for bone metastases and pain 
management, but also by the introduction of new hormonal therapies like aromatase 
inhibitors and anticancer drugs such as taxanes and capecitabine.  
 
Targeted therapeutic drugs like trastuzumab improved survival in women with HER2 
over expressing breast cancer. The recombinant, humanised monoclonal antibody to 
vascular endothelial growth factor, bevacizumab, showed a promising improvement 
in progression free survival and objective response rate in combination with paclitaxel 
(64). Lapatinib in combination with capecitabine, paclitaxel or letrozole demonstrated 
an improvement in progression free survival (PFS) of HER2 positive BC when 
compared to single agent treatment with about 4 to 5 months47,48.  
 
Moreover, favourable advances have been made in the fields of surgery, 
radiotherapy and minimal invasive procedures as radiofrequency ablation of the liver 
or resection of single liver- or lung metastases49-54. 
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4.2  PATIENT- AND TUMOR CHARACTERISTICS 
Looking at the patient characteristics of this study, a relatively young patient cohort 
was diagnosed with MBC with a median age of 53 years. Other studies report a 
median age of 57-64 years 7,28,59,67. Endocrine sensitive tumours were reported in 
75% (ER+ or/and PgR+) of all cases, which is a high percentage compared to rates 
shown in other studies (33-67%)6,28,59,67.   
A synchronous metastasis was seen in 14.7% of all cases. Most studies report an 
incidence of synchronous metastases of 6-10% 1,2. The median age of these women 
was 52 years which is relatively young in comparison to other studies. Andre et all.7 
reported a median age of 59 for women with synchronous metastases. In his 
research a positive hormone receptor was seen in 52% (1987-1993) and 56% (1994-
2000) of all cases. The present study showed a positive hormone receptor in 80% of 
all women with synchronous metastases. These findings demonstrate that the group 
of women analysed in this study is difficult to compare with others (very young patient 
cohort and a high percentage of women with endocrine sensitive tumours). More 
about the difficulty to compare the outcomes of this project with others is written in 
the chapter about study limitations. HER2-positive status was reported for 34.1% of 
the study collective. Six percent were negative for all three markers.   
About 51% presented with visceral sites of metastases. This percentage is 
comparable to results of visceral metastases described in other studies, 57% 
reported by Gennari et al.6 and 54% reported by Andre et al.7 More than three 
metastatic sites in course of disease were reported for almost one third of the 
patients, which is relatively high when compared to the 10-year follow-up study by 
Falkson et al. which reported 8-24% having more than three organs with cancer55.  
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4.3 SURVIVAL 
The median overall survival of the whole study population in this analysis was 44 
months. As 22 women with local recurrence were included in the analyses, the 
overall survival for women with distant metastasis was 39 months. After adjusting for 
the significant factors in the univariate analysis, distant metastasis vs. local 
recurrence was no longer associated with worse survival outcome because of the low 
amount of women with loco-regional recurrence (n=22). T-Stage at diagnosis, triple 
negative disease, visceral metastasis and amount of metastatic sites were significant 
related to overall survival in the multivariate analysis.  
 
In most randomized trials where the efficacy of a 1st-line schedule for MBC has been 
investigated, the median survival ranged between 18-24 months4-6, although an 
increase in survival was reported in a small proportion of patients with median 
survival times of 30 months or longer 15,45,55-57. The first-line studies have PFS as 
their primary endpoint and are therefore difficult to use for finding out the overall 
survival rates for the whole treatment area of MBC.  
Most studies describing overall survival rates as primary endpoint differentiate time 
cohorts and lack in describing treatment data. S. Dawood et al.67 investigated the 
trends in survival of 15.438 women with MBC between 1988 and 2003. The results 
showed an improvement in OS in the last two decades (1988-1993:16-, 1994-1998: 
18- and 20 months between 1999 and 2003). The multivariate model indicated that 
over time women with endocrine sensitive tumours had a decreased of risk of death 
compared to women with hormone receptor-negative disease. A hypothesis this 
study puts forward is that new and more effective therapeutic agents and supportive 
measures might contribute to the survival improvement over time. But this study 
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doesn’t show any data about treatments being given to these patients. Andre et al.7 
reported survival rates of 724 women diagnosed with breast cancer and synchronous 
metastases in a 14 years period of 1987 to 2000. The median overall survival rates 
also improved over time (23 months between 1987 and 1993, and 29 months for the 
period of 1994 to 2000). His study showed an OS of 45 months for women with HR 
positive tumours and 12 months for HR negative tumours diagnosed between 1994 
and 2000. In his study only the application of taxanes was well documented. 
Trastuzumab and capecitabine were not analysed specifically. Gennari et al. also 
analysed the influence of time cohort on overall survival. This study concluded that 
survival did improve over time, with a survival of 23.6 months in 1998-2001 
compared to 18 months of the patients treated between 1983 and 1986. Gennari et 
al. found that survival was related to taxane administration, but no information was 
provided about other sequential therapies given in course of disease, or about 
targeted therapy given6 
The studies of Gennari et al. ,Andre et al. and S. Dawood et al., 6,7,67 all investigate 
overall survival for different time cohorts. The present study investigated women 
treated in the outpatient clinic between 2000 and 2005, and is therefore difficult to 
compare with the other studies. As already noted in chapter 4.2, the patients 
characteristics of this research differ with others.  
 
In particular, the wide use of trastuzumab in the management of HER2 
overexpressing MBC has markedly improved the prognosis of this subset of patients 
when compared to the prognosis of these patients in the pre-trastuzumab era31,33. 
The median survival of 44 months in patients treated with trastuzumab because of 
HER2 overexpressing MBC in the present study underscores the advances which 
have been made in this subset of patients.  
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Analysis of the subgroup of patients with HR-positive tumours demonstrated a 
median survival time of 46 months which is in accordance with the median survival of 
this subset of patients in the study of Andre et al. (45 months)7. Andre et al. also 
reported that 39% of the women treated for synchronous metastases of breast 
cancer received new aromatase inhibitors. This is in accordance with the findings of 
the present study with respect to the percentage of aromatase inhibitors given for 
endocrine treatment of MBC (33-53% of endocrine therapies given were AI´s). 
Mouridsen et al.22 showed in a phase III clinical trial that the median OS of women 
with advanced breast cancer treated with letrozole as first-line therapy was 34 
months compared 30 months of the tamoxifen arm. There is a major importance of 
newer hormonal drugs in the actual treatment of MBC.  
 
4.4  TREATMENT OF MBC 
Data about palliative treatment were analysed to describe treatment given in this 
single-centre outpatient clinic. Following adjuvant treatment, 1st-line treatment for 
metastatic disease consisted mainly of the combination therapy of anthracyclines+ 
taxanes, followed by taxanes alone, capecitabine and vinorelbine. 2nd-line treatment 
that was given predominantly consisted of capecitabine followed by 
gemcitabine+cisplatin and vinorelbine. For patients pre-treated with anthracyclines 
and taxanes in the adjuvant setting, the AGO recommends capecitabine and 
vinorelbine as treatment. Capecitabine has been evaluated extensively. Large, multi-
centre trials showed consistent efficacy and well tolerated treatment in women pre-
treated with taxanes and anthracyclines61-63.  
In this study third-line palliative treatment consisted predominantly out of taxane, 
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capecitabine, gemicitabine+cisplatin and vinorelbine. As Figure 22 in paragraph 4.3.2 
shows, taxanes were given more frequently in 3rd-line than 1st- and 2nd- line palliative 
treatment. This can be explained by the strategy of re-induction of chemotherapy 
agents. When a longer time has passed since an agent has been applied and this 
agent showed a positive tumour response in the past, application of this agent is an 
option under good clinical conditions. In the same manner re-induction might be 
applied with endocrine treatment as well during the course of treatment.  
 
Our data were also used to calculate the total number of chemotherapeutic 
sequences given in course of disease. The 27 women is this analysis who did not 
receive any chemotherapeutic treatment had such a good prognosis because of HR 
positive disease which could be treated well with endocrine agents and had no 
visceral metastases, or had bone metastasis and were well treated with 
bisphosphonates.  
Many patients were treated with more than four sequences (35%) of chemotherapy.  
Women with 1-3 sequential chemotherapies had a median OS of 40 [95% CI 32-48] 
months, patients with more than 6 sequential palliative chemotherapies in the course 
of disease had a median OS of 47 months [95% CI 40-54].  
 
Analyses of endocrine treatment showed the influence of newer endocrine agents in 
the current treatment guidelines. The percentage of aromatase inhibitors given within 
the endocrine treatment was calculated (33-53% for the different groups).  
Clinical trials of the third generation aromatase inhibitors; anastrozole, letrozol and 
exemestan, led to an improvement in the 1st-line treatment of MBC. These trials 
showed improvement in response rate, but did not show an advantage in OS22,23. 
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This study was not designed to make any fix conclusions about the impact of 
treatment modalities on survival as the patient cohort is too small and too selective. 
Nevertheless some hypotheses could be put forward. The patients who received 
more cytostatic treatment sequences might have had favourable prognostic factors 
e.g. by slow progression due to tumorbiology which led to a higher number of 
treatment adjustments during course of disease. On the other side, improvement of 
survival might here be achieved by an accurate step by step escalation of many 
different treatment modalities by medical oncologists.   
 
Further investigation of the optimal sequences of endocrine- and chemotherapeutic 
treatment on survival of MBC, taking in concern prognostic factors for MBC e.g. 
receptor stage, amount of metastases and site of metastases as well as disease free 
interval64, is needed to support any conclusions about potential influence of these 
treatment regimens on overall survival.   
 
Another question to ask is whether treatment in specialized centres contributes to 
survival improvement. Improvement in OS outcome of women treated in this 
university outpatient clinic could be due to the fact that treatment is given in a 
multidisciplinary setting.  At weekly intervals surgeons, gynaecologists, pathologists, 
radiological oncologists, radiologist, psycho-oncologist and medical oncologist come 
together to discuss difficult decisions to be made about treatment of breast cancer 
patients, which results in the best optimal care of MBC patients.  
This study was not developed to make any conclusion about this collaboration, 
however the evidence to date suggests that loco-regional treatment of metastatic 
disease, e.g. radiofrequency ablation or resection of metastasis, is improving over 
time40,42,49,65. In this study, 31 patients underwent local-regional procedures such as 
74 
 
resection of metastases (n=14, 6.0%) or radiofrequency ablation (n=17, 7.3%).  
Patients with single lung metastases showed an OS of 56 months and 50 months for 
women with singular hepatic lesions. Patients with these types of metastatic patterns 
might be seen more frequently in specialized centres offering more options in loco-
regional treatment. Multidisciplinary treatment might contribute to improve survival in 
the same manner as newer and more powerful agents do. 
  
Despite all advances in the management of MBC, there are still remaining problems 
as expressed by the dismal prognosis of those patients with triple negative tumours 
(16 months). The lack of any improvement of survival in this subgroup underscores 
the advances which have been undertaken in patients who are candidates for 
targeted immunotherapeutic strategies or anti-endocrine treatments. 
 
 
4.5  LIMITATIONS OF THE STUDY 
It is important to critically evaluate the results of this project. The present study has 
certain limitations concerning the study population and the good survival outcomes. 
The first limitation to note is the median age of 53 years at diagnosis of metastatic 
breast cancer. This relatively young patient cohort might be one of the reasons for 
good survival outcomes. The second limitation is that the median interval between 
primary tumor and metastatic relapse, which is one of the most important prognostic 
factors in MBC60, amounts to 35.5 months. This relatively long disease-free interval 
probably induced a bias due to selection of patients with a better prognosis. The third 
limitation is the high percentage (75%) of endocrine sensitive tumours (ER+ or/and 
PgR+). Endocrine sensitive tumours have better prognostic outcomes. All these 
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study limitations induce a bias in the patient selection and contribute to the improved 
survival outcomes.  
 
It is also critical to note that some patients (n=22) with locoregional metastases are a 
part of the study population. These women have a very good prognosis. Figure 18 
shows the differences between this group and women with distant metastases. 
However, the 210 women with distant metastases had a median OS of 39 months, 
which shows as well the improvement in OS. 
 
As already mentioned the patient population of this study only represents 1.6% of all 
breast cancer patients in the catchment area of the tumor centre of Munich. This 
makes it difficult to compare the outcomes with the outcomes noted in the study of 
Schlesinger-Raab et al. 44 
 
The present study is limited by a number of biases inherent with the retrospective 
design and all results are explorative. As all patients who were well documented and 
had all of the treatments in the outpatient clinic of the medical oncology department 
were included in this research without having clearly defined in- and exclusion 
criteria, these results are difficult to compare with other retrospective or prospective 
studies. Many papers report improvements in overall survival over time, as they 
compared time cohorts. A comparison with these studies is not possible because the 
present study did not indicate different time cohorts. 
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4.6 CONCLUSIONS 
This retrospective single-centre analysis was made to investigate the overall survival 
rates in the outpatient clinic of the oncology department. The results of this study are 
all explorative and should be interpreted with caution. The study shows a small 
patient cohort with improved overall survival rates as seen in the last decades by 
others 7,57,66. Reasons for these outcomes are difficult to investigate. A bias due to 
centre specific selection is given. It is reasonable to think that younger, more mobile 
and ambitious women will consult a university hospital for treatment. The median age 
of 53 years confirms this statement. 
 
This study looked at the treatment being given in the outpatient clinic. These data are 
descriptive. They show a step by step escalation of all treatment modalities according 
to standard guidelines and individualized clinical requirements of MBC patients in a 
centre offering multidisciplinary treatment. Whether innovative medicine, multiple 
cycles of therapies and a multidisciplinary treatment approach contribute to these 
good outcomes is debatable. On the one hand is it obvious that women who survive 
longer with cancer receive more therapies, on the other hand it cannot be ruled out 
that a step by step escalation of all treatment modalities according to standard 
guidelines and individualized clinical requirements in a centre offering 
multidisciplinary treatment might contribute to the clearly improvement in survival 
outcome reported in this study. 
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